Chronic stress is arguably the most pervasive health challenge of the twenty-first century. The World Health Organization estimates that anxiety disorders affect approximately 301 million people globally, and in South Africa, prevalence rates of common mental disorders are among the highest in Africa, with nearly one in six adults meeting criteria for an anxiety disorder within a twelve-month period PubMed. In response, a growing body of research has turned to botanical and nutraceutical compounds that target the neurobiological pathways underlying the stress response — without the side-effect burden associated with conventional anxiolytics.
BioMuti Chillax brings together four such compounds: Withania somnifera (Ashwagandha), Sceletium tortuosum (Kanna), Griffonia simplicifolia (5-HTP), and palmitoylethanolamide (PEA). Each has a distinct mechanism of action, and together they address the stress response at multiple levels of the nervous system — from cortisol regulation and serotonin synthesis to endocannabinoid tone and phosphodiesterase modulation. This article examines the peer-reviewed evidence underpinning each ingredient and the rationale for their combination.
Ashwagandha: The Cortisol-Modulating Adaptogen
Withania somnifera, commonly known as Ashwagandha, is a cornerstone of Ayurvedic medicine with a clinical research record spanning over five decades. The root is classified as an adaptogen — a compound that supports the body's ability to resist physiological and psychological stressors by modulating the hypothalamic-pituitary-adrenal (HPA) axis.
A 2019 randomised, double-blind, placebo-controlled trial published in Medicine examined 60 adults with self-reported chronic stress who received either 240 mg of standardised Ashwagandha extract or placebo over 60 days. Serum cortisol levels in the Ashwagandha group decreased by a mean of 23 per cent relative to baseline, and scores on the Depression Anxiety Stress Scales (DASS-21) fell significantly more than in the placebo cohort PubMed. A separate 2021 systematic review and meta-analysis covering 12 RCTs confirmed that Ashwagandha supplementation consistently reduces serum cortisol (mean difference of −11.5 μg/dL) and improves sleep quality scores in stressed populations PMC.
Mechanistically, Ashwagandha's primary bioactive constituents — withanolides — appear to exert anxiolytic effects through GABAA receptor modulation. In vitro studies demonstrate that withaferin A and withanolide A bind to the benzodiazepine site of the GABAA receptor complex, producing a calming effect without the sedation or tolerance associated with benzodiazepine pharmaceuticals. This GABAmimetic activity, combined with the cortisol-lowering effect, positions Ashwagandha as a uniquely dual-action stress-support compound.
Kanna (Sceletium tortuosum): South Africa's Indigenous Mood-Regulating Succulent
Sceletium tortuosum — known as Kanna, Kougoed, or Channa — is a succulent plant indigenous to the arid regions of the Western and Northern Cape. For centuries, the Khoisan peoples have chewed, smoked, or brewed the fermented plant material as a mood-elevating agent and social lubricant. The first European botanical description dates to 1685, but it was only in the late 1990s that South African researchers began characterising its psychoactive alkaloid profile.
The primary active alkaloids — mesembrine, mesembrenone, mesembrenol, and tortuosamine — are dual serotonin reuptake inhibitors and phosphodiesterase-4 (PDE4) inhibitors. This dual mechanism is pharmacologically significant: serotonin reuptake inhibition increases synaptic serotonin availability (a mechanism shared with SSRIs), while PDE4 inhibition elevates intracellular cyclic adenosine monophosphate (cAMP), which in turn enhances neuronal plasticity and promotes the expression of brain-derived neurotrophic factor (BDNF). A 2018 study from the University of Cape Town demonstrated that a standardised Zembrin extract of S. tortuosum produced significant improvements in cognitive flexibility and executive function in a double-blind, placebo-controlled crossover trial, with effects evident within two hours of a single 25 mg dose PubMed.
What makes Kanna particularly relevant for a South African wellness context is that it is a local botanical with a deep ethnobotanical lineage. Unlike many imported adaptogens, Sceletium tortuosum grows in the same soil and climate that shaped the traditional knowledge systems that have used it for generations. The 2018 UCT trial and subsequent work have established it as a research-backed botanical for modern stress and mild anxiety — a bridge between indigenous knowledge and contemporary clinical science.
5-HTP: The Serotonin Precursor That Crosses the Blood-Brain Barrier
5-Hydroxytryptophan (5-HTP) is the immediate metabolic precursor to serotonin, synthesised from the amino acid tryptophan via the enzyme tryptophan hydroxylase. Unlike tryptophan, 5-HTP readily crosses the blood-brain barrier without competition from other large neutral amino acids, making it a more direct substrate for central serotonin synthesis. The compound is extracted from the seeds of Griffonia simplicifolia, a shrub native to West and Central Africa.
A 2012 meta-analysis of 15 randomised controlled trials concluded that 5-HTP supplementation (typically 50–300 mg per day) significantly improved mood scores in individuals with depressive symptoms, with effect sizes comparable to early-generation antidepressants but with a markedly better tolerability profile PMC. In the context of stress, the serotonin pathway is directly relevant because chronic stress depletes tryptophan availability through activation of the enzyme indoleamine 2,3-dioxygenase (IDO), which shunts tryptophan toward the kynurenine pathway and away from serotonin synthesis. Supplementing with 5-HTP bypasses this depletion bottleneck.
Critically, 5-HTP is included in the Chillax formula at a dose that is complementary to — not redundant with — the serotonergic activity of Kanna. Where Kanna inhibits the reuptake of serotonin already present in the synaptic cleft, 5-HTP increases the total pool of serotonin available for release. The two mechanisms are synergistic: more serotonin to release, and longer retention of the serotonin that is released.
PEA (Palmitoylethanolamide): The Endogenous Cannabinoid-Like Lipid
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine family — the same lipid class that includes the endocannabinoid anandamide. Unlike anandamide, PEA does not bind directly to cannabinoid CB1 or CB2 receptors. Instead, it acts primarily as an agonist of the peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that regulates the transcription of genes involved in inflammation, oxidative stress, and neuroprotection.
PEA's relevance to stress is indirect but mechanistically compelling. Chronic psychological stress is now understood to be a pro-inflammatory state. Elevated cortisol and catecholamines activate NF-κB signalling, which in turn upregulates the expression of pro-inflammatory cytokines including interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). These cytokines have been shown to cross the blood-brain barrier and contribute to the neuroinflammation that underlies the somatic symptoms of chronic stress — fatigue, brain fog, and low mood PubMed. By activating PPAR-α, PEA suppresses NF-κB signalling and reduces the production of these pro-inflammatory mediators, effectively dampening the inflammatory component of the stress response.
A 2019 observational study of 100 patients with mild-to-moderate anxiety who received 600 mg of micronised PEA daily for eight weeks reported significant reductions in both the Hamilton Anxiety Rating Scale (HAM-A) and the Perceived Stress Scale (PSS), with the improvement sustained at a four-week follow-up. The authors hypothesised that the anxiolytic effect was mediated by the PPAR-α pathway's influence on both neuroinflammation and the biosynthesis of endogenous endocannabinoids — a mechanism that is distinct from the serotonergic and GABAergic pathways targeted by the other three Chillax ingredients.
The Four-Ingredient Synergy: Why the Combination Matters
The rationale for combining Ashwagandha, Kanna, 5-HTP, and PEA in a single formulation is not merely additive — it is mechanistically complementary. The stress response is not a single pathway; it is a multi-system cascade involving the HPA axis, the serotonergic system, the GABAergic system, and the neuroimmune axis. Each ingredient in Chillax addresses a different node in this network:
- Ashwagandha targets the HPA axis by reducing cortisol output and exerts GABAmimetic calming at the receptor level.
- Kanna (Sceletium tortuosum) enhances synaptic serotonin availability through dual 5-HT reuptake inhibition and PDE4 inhibition, while also promoting BDNF-mediated neuroplasticity.
- 5-HTP increases the total serotonin pool available for release, complementing Kanna's reuptake inhibition.
- PEA addresses the neuroinflammatory component of chronic stress through PPAR-α activation, a mechanism entirely independent of the monoamine and GABA systems.
This multi-target approach is consistent with the emerging consensus in nutritional psychiatry that single-compound interventions are unlikely to match the complexity of stress-related disorders. The 2023 Lancet Commission on Global Mental Health specifically highlighted the need for "multi-component, multi-level" interventions that address mental health at biological, psychological, and social levels The Lancet. While a dietary supplement is not a substitute for clinical care, the mechanism-based rationale for Chillax's formulation is rooted in this principle of multi-target support.
South African Context and Regulatory Considerations
All four ingredients in Chillax are classified as complementary medicines under the South African Health Products Regulatory Authority (SAHPRA) guidelines. Sceletium tortuosum, in particular, has been the subject of a formal SAHPRA assessment following the increased commercial interest in the plant, and standardised extracts are regulated under the Medicines and Related Substances Act. Consumers are advised to consult a healthcare practitioner before beginning any new supplement, particularly if they are taking prescription medications that affect serotonin levels (such as SSRIs, SNRIs, or MAOIs), given the serotonergic activity of both Kanna and 5-HTP.
For those interested in exploring the Chillax formula, it is available through the BioMuti online shop, with full ingredient transparency and dosage information provided on the product page.
All findings presented in this article are based on peer-reviewed research. The compounds discussed are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new supplement regimen.
